首页> 美国卫生研究院文献>other >SINGLE AGENT CARBOPLATIN VERSUS CARBOPLATIN PLUS PEGYLATED LIPOSOMAL DOXORUBICIN IN RECURRENT OVARIAN CANCER: FINAL SURVIVAL RESULTS OF A SWOG (S0200) PHASE 3 RANDOMIZED TRIAL

【2h】

SINGLE AGENT CARBOPLATIN VERSUS CARBOPLATIN PLUS PEGYLATED LIPOSOMAL DOXORUBICIN IN RECURRENT OVARIAN CANCER: FINAL SURVIVAL RESULTS OF A SWOG (S0200) PHASE 3 RANDOMIZED TRIAL

机译：单一试剂卡铂卡铂VERsUs pLUs pEG化脂质体多柔比星复发性卵巢癌：将sWOG（s0200）FINaL存活结果3期随机试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

ObjectivesRandomized phase 3 trials have demonstrated the utility of a regimen of carboplatin plus pegylated liposomal doxorubicin (PLD) in recurrent ovarian cancer, and have provided provocative data suggesting a substantially lower risk of carboplatin-associated hypersensitivity if PDL is delivered in combination with the platinum agent.

著录项

期刊名称 other
作者
Maurie Markman; James Moon; Sharon Wilczynski; Ana Maria Lopez; Kendrith M. Rowland Jr.; David P. Michelin; Victor J. Lanzotti; Garnet L. Anderson; David S. Alberts;
展开▼
作者单位

展开▼
年(卷),期 -1(116),3
年度 -1
页码 323–325
总页数 7
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial. [J] . Markman M, Moon J, Wilczynski Gynecologic Oncology: An International Journal . 2010,第3期

机译：单药卡铂与卡铂加聚乙二醇化脂质体阿霉素治疗复发性卵巢癌：SWOG（S0200）3期随机试验的最终生存结果。
2. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients [J] . U Wagner, C Marth, R Largillier, British Journal of Cancer . 2012,第4期

机译：聚乙二醇化脂质体阿霉素和卡铂与紫杉醇和卡铂在铂敏感型卵巢癌患者中进行的III期GCIG CALYPSO试验的最终总体生存结果
3. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. [J] . Pignata S, Scambia G, Ferrandina G, Journal of Clinical Oncology . 2011,第27期

机译：卡铂加紫杉醇与卡铂加聚乙二醇化脂质体阿霉素作为卵巢癌患者的一线治疗药物：MITO-2随机III期试验。
4. PHASE III COMPARISON OF CARBOPLATIN VERSUS CARBOPLATIN AND DOXORUBICIN FOR THE ADJUVANT TREATMENT OF APPENDICULAR OSTEOSARCOMA: INTERIM ANALYSIS [C] . Katherine Skorupski, Justin Uhl, Stephen Shaw, Annual Conference of the Veterinary Cancer Society . 2009

机译：Carboplatin与Carboplatin和多柔比星的相位III比较，用于辅助骨肉瘤的佐剂治疗：临时分析
5. The Use Of Carboplatin and Cyclosporin A In The Treatment of Recurrent Epithelial Ovarian Cancer. [D] . Overton, Eve. 2016

机译：卡铂和环孢菌素A在复发性上皮性卵巢癌治疗中的应用。
6. RANDOMIZED TRIAL OF PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) PLUS CARBOPLATIN VERSUS CARBOPLATIN IN PLATINUM-SENSITIVE (PS) PATIENTS WITH RECURRENT EPITHELIAL OVARIAN OR PERITONEAL CARCINOMA AFTER FAILURE OF INITIAL PLATINUM-BASED CHEMOTHERAPY (SOUTH WEST ONCOLOGY GROUP PROTOCOL S0200) [O] . David S. Alberts, P. Y. Liu, Sharon P. Wilczynski, -1

机译：在华氏200度以上的初始白热病患者（最初的化疗）后复发性上皮性卵巢或腹膜癌的铂敏感性（PS）患者中聚脂脂质体阿霉素（PLD）加卡铂与卡铂的随机对照试验
7. Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: Final survival results of a SWOG (S0200) phase 3 randomized trial [O] . Maurie Markman, James Moon, Sharon Wilczynski, 2010

机译：单体剂卡铂与卡铂加上分子蛋白复发性卵巢癌中的聚乙二醇脂质蛋白：猪的最终存活结果（S0200）第3期随机试验

SINGLE AGENT CARBOPLATIN VERSUS CARBOPLATIN PLUS PEGYLATED LIPOSOMAL DOXORUBICIN IN RECURRENT OVARIAN CANCER: FINAL SURVIVAL RESULTS OF A SWOG (S0200) PHASE 3 RANDOMIZED TRIAL

摘要

著录项

相似文献

相关主题

期刊订阅